Suven Life Sciences Limited — Updates, 13-08-2025: Press Release

Suven Life Sciences reported consolidated revenue of **Rs 2.47 Cr** and a net loss of **Rs 51.52 Cr** for the latest quarter. The company significantly advanced its clinical pipeline: SUVN-502 Phase 3 study (Alzheimer's) crossed 43% enrollment, SUVN-G3031 is preparing for Phase 3 (Narcolepsy), and SUVN-911 initiated Phase 2B (MDD). SUVN-D4010 and SUVN-I6107 are also progressing. Suven successfully raised **Rs 857.64 Cr** via convertible warrants, strengthening its financial position for ongoing R&D.